Weedstocks Newswire Feed
Evolve Formulas Introduces New Hemp-Derived Product to Indiana Market, Launching in Mid-September
DENVER, Sept. 11, 2018 /CNW/ -- NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF), the biotechnology leader behind the patented NanoSphere Delivery System™, has entered into a revenue-sharing agreement to expand its Evolve Formulas product line to Indiana with Jeff DeHart, Managing Member of Evolve Formulas of Indiana, LLC. Under the agreement, NanoSphere will introduce a new, hemp-derived offering to the Indiana market. The NanoSerum™ Hemp products will be available for purchase in mid-September.
NanoSerum™ Hemp, like the other Evolve Formulas products, will leverage NanoSphere Health Sciences' next-generation NanoSphere Delivery System™ to provide fast-acting relief from pain and inflammation. Similar to marijuana, hemp is derived from the cannabis plant and carries a vast range of medical benefits; however, it is genetically distinct and does not contain THC. The hemp-derived NanoSerum™ will be available in 5ML and 10ML sizes. There are already 1,500 pre-orders to-date.
"With a proven track record of success already under our belt in Colorado—we are eager to continue Evolve Formulas' expansion by forging a path into the Midwest with an exciting new product, which delivers the benefits of hemp precisely and effectively," said Robert Sutton, CEO and Chairman of NanoSphere Heath Sciences and Evolve Formulas. "Bringing our unique delivery system to the residents of Indiana will serve to not only educate the public on the extraordinary medical potential of hemp, but also set the bar for a high standard of hemp-derived products in this untapped market."
NanoSphere Health Sciences utilizes a method of nano-encapsulating cannabis molecules in lipid membranes so they can be transported through layers of the skin and into the bloodstream in minutes. This provides rapid results, precise dosages and high bioavailability of cannabis which is ideal for localized pain and inflammation, as well as providing systemic therapy and relief from anxiety. With plans to expand into pharmaceutical, nutraceutical, cosmeceutical and animal health divisions in the coming years, the new hemp serum is another example of how NanoSphere's technology can be applied to various formats and industries.
TORONTO, Sept. 11, 2018 /CNW/ - Newstrike Brands Ltd. (TSX-V:HIP) ("Newstrike" or the "Company"), is pleased to announce that it has been approved for graduation from Tier 2 to Tier 1 issuer status on the TSX Venture Exchange (the "TSXV").
"Advancing to a Tier 1 listing on the TSXV reflects Newstrike's continued progress and development as a company with Canada's legalized adult-use cannabis market fast approaching," said Jay Wilgar, Chief Executive Officer and Chairman of Newstrike. "We're excited to reach this listing milestone and we look forward to others as we execute our strategy to build Up Cannabis as a premier adult-use cannabis brand across Canada."
The TSXV classifies issuers into different tiers based on standards including historical financial performance, stage of development and financial resources. Tier 1 is the TSXV's premier tier and is reserved for the TSXV's most advanced issuers.
About Newstrike and Up Cannabis
Newstrike is the parent company of Up Cannabis, a licensed producer of cannabis that is licensed to both cultivate and sell cannabis in all acceptable forms. Newstrike, through Up Cannabis and together with select strategic partners, including Canada's iconic musicians The Tragically Hip, is developing a diverse network of high quality cannabis brands. For more information, visit http://www.up.ca or http://www.newstrike.ca
FSD Pharma Issues 40,000,000 Stock Options to Director Dr. Raza Bokhari Conditional on NASDAQ listing
CSE: HUGE OTC: FSDDF FRA: 0K9
TORONTO, Sept. 11, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) announces that pursuant to its Stock Option Plan, the Board approved the grant of 3,000,000 stock options for class B subordinate voting shares of the Company (the "Options") on August 14, 2018 to Dr. Raza Bokhari following his appointment as a Director. The Options vest immediately and are exercisable at a price of $0.13 for a period of five years. The Company has also cancelled 15,000,000 stock options that had been previously issued at $0.05.
The Board has also approved an additional grant of 40,000,000 Options to Dr. Bokhari exercisable at a price of $0.74 for a period of five years. The Options shall only vest and become exercisable upon the completion of the following conditions:
Stock Option Plan
InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
VANCOUVER, Sept. 11, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that the Company's research partner, University of British Columbia ("UBC"), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada ("NSERC") for their collaborative efforts with InMed in the biosynthesis of cannabinoids (the "Collaboration").
Under the terms of the grant, the NSERC has committed funding of C$136,000 towards the Collaboration over the course of three years. The Collaboration, entitled 'Microbial metabolic engineering for cannabinoid biosynthesis', which originally commenced in May 2015, targets development of a microbial-based cannabinoid expression system for the manufacture of individual cannabinoid drugs for treating diseases with high unmet medical needs.
InMed's Vice President, Pre-Clinical Research & Development, Eric Hsu, Ph.D., commented, "We are honored that our trusted, world-class research partner, Dr. Yadav at UBC, has received this prestigious grant from the NSERC. Through our continued research effort on this program with UBC, we remain optimistic that the development of our proprietary biosynthesis platform technology will result in commercial-scale manufacturing of cannabinoids."
"We would like to take this opportunity to extend our gratitude to the NSERC for their vote of confidence in our cutting-edge work," added Vikramaditya G. Yadav, Ph.D., Assistant Professor in the Department of Chemical & Biological Engineering. "The successful completion of this Collaboration will not only advance the Company's manufacturing capabilities and its R&D pipeline, but also provide immense social and strategic benefit to Canada."
About InMed: InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
Prince Edward Island Cannabis Management Corporation Partners with Lift & Co. to Train Cannabis Retail Staff
Lift & Co. Cannabis Retail Training for PEICMC staff developed in partnership with MADD Canada
CHARLOTTETOWN and TORONTO, Sept. 11, 2018 /CNW/ - Today, Lift & Co. announced a second public-sector, multi-year agreement to train cannabis retail staff in preparation for federal legalization on October 17. Starting this September, Prince Edward Island Cannabis Management Corporation ("PEICMC") employees will receive training through Lift & Co.'s Cannabis Retail Training Certification (the "Certification"), which leverages Lift & Co.'s years of experience educating cannabis consumers in partnership with MADD Canada's recognized expertise in responsible use.
PEICMC employees will receive training on selling and safety through a series of online lessons, developed by Lift & Co. and MADD Canada. Topics covered by the Certification include public health and harm reduction, law and liabilities, and working with different cannabis customers, among others.
"Education for frontline cannabis retail employees is essential to ensure an informed consumer base," said Matei Olaru, CEO of Lift & Co. "Lift & Co. is committed to providing leading information to Canadian retailers through our platform. We're thrilled to bring this level of sophisticated knowledge to the staff at PEICMC and prepare them for the upcoming legalization of cannabis."
"We're very excited to partner with Lift & Co. and MADD Canada to provide a comprehensive training program to PEICMC employees," said Andrew MacMillan, CEO of PEICMC. "This program will ensure that our cannabis retail team is well-trained and well-prepared to talk to customers about responsible cannabis usage guidelines and social responsibility principles which in turn will contribute to the success of the recreational cannabis industry on PEI."
Natura submits application to Health Canada for third and fourth flowering rooms in Leamington facility
TORONTO, Sept. 11, 2018 /CNW/ - Natura Naturals Inc. ("Natura") has submitted an application to Health Canada requesting approval to add "Grow Space 3" and "Grow Space 4" to their current ACMPR license. Grow Space 3 provides approximately 39,000 square feet of flowering area and Grow Space 4 provides approximately 47,000 square feet of flowering area. The two spaces combined have an anticipated dry harvest yield of 11,000 kilograms of medical-grade cannabis per year.
This application to Health Canada follows the previous approval by Health Canada of Grow Space 2, a 34,500 square foot flowering area and Grow Space 1, a 30,000 square foot growing area at the Leamington facility. President and CEO of Natura, Ben Nikolaevsky, said that this additional application to Health Canada continues to build on Natura's production momentum.
"The completion and submission of the application for Grow Space 3 and 4 now largely completes Phase 1 of our best-in-class facility. This approval, once received from Health Canada, adds significant production capability for Natura." Nikolaevsky stated.
Once approved, this additional capacity is expected to bring the facility's total medical-grade cannabis production to approximately 17,000 kg per year.
For more information, please visit: www.naturanaturals.com
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
The licensed cannabis producer can now sell medicinal cannabis oils in Canada
CHARLOTTETOWN, Sept. 11, 2018 /CNW/ - FIGR, Inc. is pleased to announce its subsidiary, Canada's Island Garden (CIG), has received approval from Health Canada for its most recent license amendment request, allowing for the sale of medicinal cannabis oils. The license is issued through Health Canada, pursuant to the Access to Cannabis for Medical Purposes Regulations. The sales license authorizes CIG to sell medicinal cannabis oil products. The company previously received its sales license for dried cannabis (flower) on February 7, 2017.
"Securing our license to sell cannabis oils marks a significant milestone for our company. As the only licensed producer in Prince Edward Island, we can now participate in the derivative cannabis market by further expanding our product line for patients and offering an alternative to inhaled products," said Edwin Jewell, president of CIG.
"Our team has been working diligently to meet Health Canada's requirements. We are very excited to move into the next phase of our growth. Obtaining this license means we can now sell both medicinal dried cannabis and medicinal cannabis oil products."
OTTAWA, Sept. 11, 2018 /CNW/ - National Access Cannabis Corp. ("NAC" or the "Company") (TSXV: META), Canada's best practices leader in delivering secure, safe, and responsible access to legal cannabis today announced it has closed the previously announced acquisition (the "Acquisition") of 100% of the shares of Alberta-based The Green Company Ltd. ("NewLeaf").
"Between our organic retail opportunities, this Acquisition and our Strategic Alliance with The Second Cup Ltd., NAC is positioned to become one of Canada's largest national cannabis retailers," said Mark Goliger, CEO of NAC. "We have set aggressive but achievable goals over the next 18 months and expect to open up to 220 retail cannabis locations over that period. I'd like to thank our management team, Board of Directors and shareholders for their support as we enter the most exciting period in our company's history."
Previous announcements regarding NewLeaf may be found through the following links:
September 10, 2018 – National Access Cannabis Exercises Option to Acquire 100% of Alberta-Based The Green Company Ltd. and Announces Changes to Board of Directors
Invictus Signs Arrangement Agreement for Spinout of Poda and Announces Annual General and Special Meeting Date
VANCOUVER, Sept. 11, 2018 /CNW/ - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) announced today that it has entered into a non-arm's length arrangement agreement dated September 10, 2018 (the "Agreement"), with Poda Technologies Inc. ("Poda") to give effect to the spin-out transaction previously announced on August 21, 2018.
The Agreement, a copy of which will be available under the Company's profile on SEDAR at www.sedar.com, sets out the terms of the statutory plan of arrangement (the "Arrangement") involving Invictus, its security holders, and Poda, which Arrangement, if completed, will result in shareholders of Invictus as at the effective date of the Arrangement (the "Effective Date") being entitled to receive, for each common share of Invictus (an "Invictus Share") held as at such date:
(a) one post-Arrangement common share of Invictus (a "New Invictus Share"); and
(b) one common share of Poda (a "Poda Share").
Holders of outstanding Invictus warrants ("Warrants") immediately prior to the Effective Date will receive, upon exercise of each such Warrant at the same original exercise price, one New Invictus Share and one Poda Share, in lieu of the one Invictus Share that was issuable upon exercise of such Warrant immediately prior to the Effective Date.
First Hemp Extract to Achieve Highly Sought-After Self-Affirmed GRAS Status Designation
LAS VEGAS, Sept. 10, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our” or “we”) preeminent supplier and manufacturer of hemp-derived phytocannabinoids including CBD oil, announced today that the Company’s hemp-derived CBD gold extract which includes all of PlusCBD Oil™ Gold Formula product line, has received self-affirmed Generally Recognized as Safe (GRAS) status in accordance with stringent U.S. Food and Drug Administration (FDA) safety guidelines. CV Sciences is the only hemp CBD nutraceutical company to invest in the scientific evidence necessary to achieve this sought-after designation, recognizing an ingredient as presumably safe among experts under the conditions of its intended use.
Joseph Dowling, Chief Executive Officer at CV Sciences, commented, “We are committed to building consumer confidence and trust in the safety and quality of our products, supported by scientific evidence. This milestone significantly advances our leadership in this space and provides us with opportunities to broaden consumer access to our products, while removing any doubts on the safety and benefits of our products. We are proud to be the first and only company to obtain GRAS self-affirmation on a hemp extract and believe this is a milestone for CV Sciences as well as the entire hemp CBD industry.”
As demand for CBD continues to increase, research has cited tremendous growth including Hemp Business Journal, an industry market research publication which projects that the CBD market will reach $2.1 billion by 2020. CV Sciences’ vertically integrated process allows for Full Traceability - From Seed to Shelf™ and ensures product quality and safety for its complete line of finished products.
About CV Sciences, Inc.